Erratum: Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer (Oncogenesis (2014) 3 (e100)Doi:10.1038/oncsis.2014.14);Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer

Oncogenesis

Volumn 3, Issue 4, 2014, Pages

  Al Ejeh, F ^a   Simpson, P T ^b   Sanus, J M ^b   Klein, K ^a   Kalimutho, M ^a   Shi, W ^a   Miranda, M ^a,c   Kutasovic, J ^b   Raghavendra, A ^b   Madore, J ^b   Reid, L ^b   Krause, L ^a   Chenevix Trench, G ^a   Lakhani, S R ^b,c,d   Khanna, K K ^a,c  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

aggressive breast cancer; chromosomal instability; chromosome segregation; kinetochore attachment; therapeutic targets; Triple negative breast cancer

Indexed keywords

DOCETAXEL; ESTROGEN RECEPTOR; NDC80 COMPLEX; PBK PROTEIN; PROTEIN; SMALL INTERFERING RNA; TPX2 PROTEIN; TTK PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER CELL LINE; CANCER MORTALITY; CELL SURVIVAL; CHROMOSOMAL INSTABILITY; CHROMOSOME SEGREGATION; DISTANT METASTASIS; GENE EXPRESSION; HUMAN; META ANALYSIS; MITOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER;

EID: 84925877676     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2014.41     Document Type: Erratum

References (66)

1. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008; 26: 1275-1281.
2. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
3. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012; 30: 1796-1804.
4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98: 10869-10874.
5. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
6. Weigelt B, Hu Z, He X, Livasy C, Carey LA, Ewend MG et al. Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res 2005; 65: 9155-9158.
7. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96-107.
8. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
9. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New Engl J Med 2004; 351: 2817-2826.
11. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006; 98: 1183-1192.
12. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-1246.
13. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V et al. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer. Clin Cancer Res 2008; 14: 2601-2608.
14. Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004; 5: 607-616.
15. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Nl Cancer Inst 2006; 98: 262-272.
16. Cheng WY, Ou Yang TH, Anastassiou D. Biomolecular events in cancer revealed by attractor metagenes. PLoS Comput Biol 2013; 9: e1002920.
17. Cheng WY, Ou Yang TH, Anastassiou D. Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med 2013; 5: 181ra150.
18. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM et al. A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 2005; 65: 4059-4066.
19. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY) 2004; 6: 1-6.
20. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 2006; 38: 1043-1048.
21. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012; 486: 346-352.
22. Haibe-Kains B, Desmedt C, Rothe F, Piccart M, Sotiriou C, Bontempi G. A fuzzy gene expression-based computational approach improves breast cancer prognostication. Genome Biol 2010; 11: R18.
23. Szasz AM, Li Q, Eklund AC, Sztupinszki Z, Rowan A, Tokes AM et al. The CIN4 chromosomal instability qPCR classifier defines tumor aneuploidy and stratifies outcome in grade 2 breast cancer. PLoS ONE 2013; 8: e56707.
24. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q et al. An online survival analysis tool to rapidly assess the effect of 22 277 genes on breast cancer prognosis using microarray data of 1809 patients. Breast Cancer Res Treat 2010; 123: 725-731.
25. Rizzolio F, Tuccinardi T, Caligiuri I, Lucchetti C, Giordano A. CDK inhibitors: from the bench to clinical trials. Curr Drug Targets 2010; 11: 279-290.
26. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med 2012; 209: 679-696.
27. Manchado E, Guillamot M, Malumbres M. Killing cells by targeting mitosis. Cell Death Differ 2012; 19: 369-377.
28. Janssen A, Medema RH. Mitosis as an anti-cancer target. Oncogene 2011; 30: 2799-2809.
29. Stucke VM, Sillje HH, Arnaud L, Nigg EA. Human Mps1 kinase is required for the spindle assembly checkpoint but not for centrosome duplication. EMBO J 2002; 21: 1723-1732.
30. Nagalla S, Chou JW, Willingham MC, Ruiz J, Vaughn JP, Dubey P et al. Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol 2013; 14: R34.
31. Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122: 1138-1143.
32. Roylance R, Endesfelder D, Gorman P, Burrell RA, Sander J, Tomlinson I et al. Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2183-2194.
33. Birkbak NJ, Eklund AC, Li Q, McClelland SE, Endesfelder D, Tan P et al. Paradoxical relationship between chromosomal instability and survival outcome in cancer. Cancer Res 2011; 71: 3447-3452.
34. Janssen A, van der Burg M, Szuhai K, Kops GJ, Medema RH. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 2011; 333: 1895-1898.
35. Kolodner RD, Cleveland DW, Putnam CD. Cancer. Aneuploidy drives a mutator phenotype in cancer. Science 2011; 333: 942-943.
36. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009; 136: 823-837.
37. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
38. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis 2011; 32: 650-658.
39. Kusumbe AP, Bapat SA. Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 2009; 69: 9245-9253.
40. Liang Y, Zhong Z, Huang Y, Deng W, Cao J, Tsao G et al. Stem-like cancer cells are inducible by increasing genomic instability in cancer cells. JBiol Chem 2010; 285: 4931-4940.
41. Do TV, Xiao F, Bickel LE, Klein-Szanto AJ, Pathak HB, Hua X et al. Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion. Oncogene 2014; 33: 539-549.
42. Joshi K, Banasavadi-Siddegowda Y, Mo X, Kim SH, Mao P, Kig C et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem cells 2013; 31: 1051-1063.
43. Gu C, Banasavadi-Siddegowda YK, Joshi K, Nakamura Y, Kurt H, Gupta S et al. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem cells 2013; 31: 870-881.
44. Hebbard LW, Maurer J, Miller A, Lesperance J, Hassell J, Oshima RG et al. Maternal embryonic leucine zipper kinase is upregulated and required in mammary tumor-initiating cells in vivo. Cancer Res 2010; 70: 8863-8873.
45. Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 2011; 19: 701-714.
46. Chan CH, Morrow JK, Li CF, Gao Y, Jin G, Moten A et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013; 154: 556-568.
47. Daniel J, Coulter J, Woo JH, Wilsbach K, Gabrielson E. High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci USA 2011; 108: 5384-5389.
48. Maire V, Baldeyron C, Richardson M, Tesson B, Vincent-Salomon A, Gravier E et al. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS ONE 2013; 8: e63712.
49. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, Tubiana-Hulin M et al. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 2007; 8: 1071-1078.
50. Gluck S, Ross JS, Royce M, McKenna Jr. EF, Perou CM, Avisar E et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/-trastuzumab. Breast Cancer Res Treatt 2012; 132: 781-791.
51. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A et al. A genomic predictor of response and survival following taxane-Anthracycline chemotherapy for invasive breast cancer. JAMA 2011; 305: 1873-1881.
52. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439: 353-357.
53. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 2011; 11: 143.
54. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 2010; 16: 5351-5361.
55. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
56. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459: 1005-1009.
57. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007; 13: 3207-3214.
58. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68: 5405-5413.
59. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P et al. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010; 28: 4111-4119.
60. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. New Engl J Med 2002; 347: 1999-2009.
61. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P et al. Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 2005; 7: R953-R964.
62. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100: 8418-8423.
63. Zhao Y, Simon R. BRB-ArrayTools Data Archive for human cancer gene expression: a unique and efficient data sharing resource. Cancer Inform 2008; 6: 9-15.
64. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102: 13550-13555.
65. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005; 365: 671-679.
66. Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med 2013; 54: 913-921.